Oct 26, 2016 • 7:00 AM EDT

Q3 2016 Quarterly Results

Quarter Ended Sep 30, 2016

142% increase in consolidated revenue to $60.8 million

150% increase in clinical genetic testing volume

Diluted EPS of ($0.07) per share and Adjusted Diluted EPS of $0.04 per share

Year-to-date cash flow from operations of $21.7 million

Company Profile

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.

Latest Quarterly Results

Q3 2016

Quarter Ended Sep 30, 2016

Latest 10-K

View Latest 10-K

NeoGenomics, Inc.

NASDAQ: NEO

Market/Symbol

Price

Change

Volume

Day Range

52 week Range

IR Contact Information

Investor Relations Steven Jones
Executive Vice President & Chief Compliance Officer
T: (239) 325-2001
sjones@neogenomics.com

Transfer Agent Standard Registrar & Transfer Company
12528 South 1840 East
Draper, UT 84020
T: (801) 571-8844